Lumos Diagnostics Holdings（ASX: LDX）已向澳大利亚证券交易所申请交易暂停，以待公司就美国食品药品监督管理局（FDA）对其Febridx检测产品CLIA豁免申请的回应发布最新消息。
该交易暂停将自2023年10月11日开盘时生效，直至公司发布相关公告或10月13日开盘时终止，以较早者为准。此举旨在确保在重要监管信息发布前，市场交易的公平性和有序性。
Febridx是公司开发的一款快速诊断产品，CLIA豁免意味着该产品可在更广泛的医疗点（如诊所、药房）由非专业人员使用，从而显著扩大其市场潜力。此次FDA的回应对于该产品在美国的商业化进程至关重要。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.